PRNewsWire
23 Jul 2026, 10:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Quest Diagnostics raised its full-year 2026 guidance for net revenues, reported diluted EPS, and adjusted diluted EPS. — Upward revisions to full-year guidance are strong bullish signals that typically drive immediate share price appreciation.
+0.80The company reported a 19.1% year-over-year increase in adjusted diluted EPS for the second quarter of 2026. — High double-digit earnings growth demonstrates strong profitability and execution of the corporate strategy.
+0.60Net revenues increased by 10.2% in Q2 2026, driven primarily by 13.1% growth in requisition volume. — Strong organic volume growth indicates increasing market demand for diagnostic services.
+0.50Continue reading
6 related stories
Top 2 movers · tap to explore
Revenue per requisition declined by 2.8% in the second quarter compared to the previous year. — Pricing pressure or a shift in test mix suggests a potential headwind to margins despite volume growth.
Which stocks this story touches
The company reported robust top- and bottom-line growth, including a 10.2% increase in net revenues and raised its full-year revenue and EPS guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
WSJ
1h ago
